Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 269 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: intravenous fluid treatment Clear all
Recruiting Phase 2 Interventional

Phosphate in Acute Pancreatitis

NCT07681050
View directory record Official record
Conditions
Pancreatitis
Interventions
Sodium Phosphate, Potassium Phosphate
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Early Phase 1 Interventional

A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure

NCT04319731
View directory record Official record
Conditions
SARS CoV-2 Infection
Interventions
Human Amniotic Fluid
Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

NCT03952637
View directory record Official record
Conditions
Lysosomal Diseases, Gangliosidosis, GM1
Interventions
AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam
Biological · Procedure · Drug + 3 more
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
6 Months to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer

NCT00992186
View directory record Official record
Conditions
Prostate Cancer
Interventions
Carlumab
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Orange City, Florida • Ann Arbor, Michigan • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Furosemide Use to Fill the Bladder of Pediatric Females Awaiting Pelvic Ultrasound

NCT05098366
View directory record Official record
Conditions
Ovarian Torsion
Interventions
Furosemide, Normal saline
Drug
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 18 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

NCT01000285
View directory record Official record
Conditions
Leukemia-Lymphoma, Adult T-Cell
Interventions
Bortezomib, Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide, Raltegravir
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Miami, Florida • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency

NCT02282527
View directory record Official record
Conditions
Alpha₁-Antitrypsin Deficiency
Interventions
Liquid Alpha₁-PI, Prolastin-C
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Denver, Colorado • Gainesville, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Not applicable Interventional

Normal Saline Versus Plasmalyte in Initial Resuscitation of Trauma Patients

NCT01270854
View directory record Official record
Conditions
Wounds and Injuries, Multiple Trauma, Disorder of Fluid Balance
Interventions
Plasmalyte A, Normal Saline
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

NCT02641561
View directory record Official record
Conditions
Post-ERCP Acute Pancreatitis
Interventions
Indomethacin, Lactated Ringer's Solution, Normal Saline, Placebo
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 6, 2026, 1:09 PM EDT
Terminated Not applicable Interventional

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

NCT02548494
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
Interventions
Glargine, IV insulin, Electrolyte Correction, Correction of Fluid Loss
Drug · Other
Lead sponsor
Chattanooga-Hamilton County Hospital Authority
Other
Eligibility
1 Year to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis

NCT01104025
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
ATG, rabbit, Etoposide, Methotrexate, hydrocortisone, Dexamethasone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration

NCT00304954
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Intravenous Daclizumab, Intravenous Infliximab, Observation, Oral Rapamycin
Drug · Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 92 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional

New Treatment Option for Pancreatic Cancer

NCT01364805
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Intravenous Vitamin C, Gemcitabine
Drug
Lead sponsor
Jeanne Drisko, MD, CNS, FACN
Other
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1Phase 2 Interventional

Zofin to Treat COVID-19 Long Haulers

NCT05228899
View directory record Official record
Conditions
COVID-19
Interventions
Zofin, Placebo
Drug · Other
Lead sponsor
ZEO ScientifiX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Newport Beach, California • North Hollywood, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 6, 2026, 1:09 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT05394116
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Garetosmab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
Los Angeles, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Not applicable Interventional Results available

A Prospective Study Evaluating the Use of Intraoperative Stroke Volume Variation Via the FloTrac Device to Guide Fluid and Vasopressor Management in Head and Neck Free Flaps

NCT02186938
View directory record Official record
Conditions
Head and Neck Cancer, Patients Requiring a Free Flap Surgery
Interventions
FloTrac
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Clonidine Versus Adenosine to Treat Neuropathic Pain

NCT00349921
View directory record Official record
Conditions
Pain
Interventions
clonidine, adenosine, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 3 Interventional

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

NCT01188187
View directory record Official record
Conditions
Prostate Cancer
Interventions
Custirsen, Docetaxel, Prednisone, Dexamethasone
Drug
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Marina del Rey, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants

NCT05395104
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Midazolam, Cefiderocol
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

NCT04930887
View directory record Official record
Conditions
Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
Interventions
Exparel (Bupivacaine Liposome), Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

NCT02810444
View directory record Official record
Conditions
Primary Immunodeficiency Disease
Interventions
IgG Next Generation (BT595)
Biological
Lead sponsor
Biotest
Industry
Eligibility
2 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Centennial, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 6, 2026, 1:09 PM EDT
Terminated Phase 2 Interventional Results available

Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)

NCT01106950
View directory record Official record
Conditions
Leukemia, Myelogenous, Acute
Interventions
Natural Killer Cells, Fludarabine, Cyclophosphamide, Denileukin diftitox, Donor lymphapheresis, IL-2
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
2 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects

NCT07285863
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Chronic Pancreatitis
Interventions
Secretin (human synthetic) - ChiRhoClin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 3 Interventional Results available

Trial of Decitabine in Patients With Acute Myeloid Leukemia

NCT00260832
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine or Supportive Care, Dacogen (decitabine) only
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
65 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
37
States / cities
Los Angeles, California • Fort Myers, Florida • Gainesville, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 6, 2026, 1:09 PM EDT